Naporafenib Clinical Trials (2026): 2 Studies for Advanced or Metastatic NRAS-mutant Melanoma & Advanced or Metastatic Solid Tumors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 Naporafenib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Advanced or Metastatic NRAS-mutant Melanoma & Advanced or Metastatic Solid Tumors) and 164 total planned enrollment. 1 Phase 3 Naporafenib trial are listed. Most recent activity: NCT06346067 (Dec 2028).
Naporafenib clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
| P3 | 1 | 1 |
Naporafenib clinical trials by indication
Advanced or Metastatic NRAS-mutant Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06346067 | ERAS-254 | P3 | active not recruiting | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) |
Advanced or Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05907304 | SEACRAFT-1 | P1 | active not recruiting | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations |
Naporafenib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ERAS-254 | NCT06346067 | P3 | active not recruiting | Advanced or Metastatic NRAS-mutant Melanoma | 78 | — |
All Naporafenib trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06346067 | ERAS-254 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | P3 | active not recruiting | 78 | Erasca, Inc. | Apr 2024 |
| NCT05907304 | SEACRAFT-1 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | P1 | active not recruiting | 86 | Erasca, Inc. | Aug 2023 |
Naporafenib clinical trials: frequently asked questions
- How many Naporafenib clinical trials are there?
- 2 Naporafenib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are Naporafenib clinical trials recruiting in 2026?
- No active Naporafenib trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Naporafenib being studied for?
- Naporafenib is being studied for Advanced or Metastatic NRAS-mutant Melanoma, Advanced or Metastatic Solid Tumors. The trials are grouped by indication on this page.
- What phase is Naporafenib in?
- Naporafenib clinical trials span 1 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Naporafenib clinical trials?
- The lead sponsor across the most Naporafenib trials is Erasca, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Naporafenibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: